[Skip to Navigation]
Sign In
March 11, 2021

Is It Time to Reevaluate Radiotherapy Omission in Older Patients With Favorable Early-Stage Breast Cancer?

Author Affiliations
  • 1Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois
  • 2Department of Radiation Oncology, New York Proton Center, New York
  • 3Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus
JAMA Oncol. 2021;7(7):965-966. doi:10.1001/jamaoncol.2021.0064

The role of adjuvant radiotherapy (RT) following breast-conserving surgery in early-stage breast cancer has been well established based on several landmark clinical trials in the 1970s.1,2 Subsequent studies3,4 have suggested that in a subgroup of patients, particularly older women with smaller estrogen receptor (ER)–positive tumors receiving antihormonal therapy, irradiation may not provide as compelling a clinically meaningful benefit. More recently, significant technical5 and practical6,7 advances in breast RT have been made, and an emphasis on individual patient-centric care has become the norm. Taken together, these factors beg the question: Is it time to reevaluate the practice of omitting RT in patients 65 years or older with favorable early-stage breast cancer?

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words